Preview Mode Links will not work in preview mode

Apr 6, 2021

Featuring a roundtable discussion with Drs Virginia F Borges, Sara Hurvitz and Ian E Krop, including the following topics:

  • Introduction
    • Impact of COVID-19 vaccinations on screening for breast cancer (0:00)
  • Management of HER2-positive early breast cancer
    • Case: A woman in her early 40s with ER/PR-positive, HER2-positive breast cancer achieves a pathologic complete response with docetaxel/trastuzumab/pertuzumab — Alan B Astrow, MD (6:30)
    • Therapeutic approach for patients with HER2-positive breast cancer and residual disease after neoadjuvant therapy (10:04)
    • Case: A woman in her early 70s with Grade III, ER/PR-negative, HER2-positive breast cancer develops shortness of breath after neoadjuvant chemotherapy — Dr Astrow (19:57)
    • Disease-specific factors in the selection of neoadjuvant therapy for patients with HER2-positive breast cancer (28:00)
    • Selection of HER2-targeted therapy in the adjuvant setting  (33:31)
  • Selection and sequencing of therapies for HER2-positive metastatic breast cancer
    • Case: A woman in her early 40s with HER2-positive breast cancer and brain metastases — Yanjun Ma, MD (36:11)
    • Case: A woman in her mid-30s with ER/PR-positive, HER2-positive breast cancer and brain metastases — Estelamari Rodriguez, MD, MPH (40:56)
    • Case: A woman in her mid-60s who presents with a large, ulcerated breast mass and is diagnosed with HER2-positive breast cancer and liver metastases — Dr Astrow (48:38)
    • Choice of initial therapy for patients with metastatic HER2-positive breast cancer (55:08)
    • Management of HER2-positive breast cancer with brain metastases; intracranial activity of tucatinib in patients with metastatic HER2-positive breast cancer (1:00:00)
    • CNS penetration and intracranial response with the antibody-drug conjugates trastuzumab deruxtecan and T-DM1; efficacy and tolerability of neratinib after disease progression on tucatinib (1:07:28)
    • Perspective on the use of hormonal therapy for patients with ER/PR-positive, HER2-positive breast cancer (1:12:45)
    • Efficacy of PARP inhibitors in patients with HER2-positive breast cancer and BRCA mutations; emerging data from the OlympiA trial evaluating olaparib as adjuvant therapy for patients with HER2-negative breast cancer and germline BRCA mutations (1:18:53)
    • Benefits and risks of the novel anti-HER2 antibody margetuximab for patients with HER2-positive advanced breast cancer (1:25:10)

CME information and select publications